비교리스트

 카트 문의
시장보고서
상품코드
1654386

파킨슨병(PD) 치료 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 약제 클래스별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Parkinson´s Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

파킨슨병 치료 시장의 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 파킨슨병 치료 시장 규모는 2025년부터 2030년까지 CAGR 5.04%를 기록할 전망이며, 2030년에는 75억 8,000만 달러에 이를 전망입니다. 이것은 PD의 새로운 치료법의 연구 개발에 대한 투자가 증가하고 있기 때문입니다. 2021년 8월 파킨슨 재단은 PD의 신규 치료 및 치료법 개발을 목적으로 하는 29개 연구 프로젝트에 연구 보조금으로 4,300만 달러를 투자할 것이라고 발표했습니다. 게다가 2021년 5월, 파킨슨 재단은 파킨슨병(PD)에 관한 연구, 케어, 교육 프로그램에 1,000만 달러를 투자한다고 발표했습니다. 이 투자는 PD로 고통받는 사람들에게 무료로 인지와 유전자 검사를 제공하는 데 도움이 될 것으로 예상됩니다.

이러한 투자 이니셔티브는 산업 성장을 뒷받침할 것으로 기대됩니다. 지난 10년간 PD 치료 부문에서는 큰 연구개발 활동이 진행되어 혁신적인 약물 전달 방법의 개발로 이어졌습니다. 부작용이 적기 때문에 이러한 최첨단 약물전달 시스템은 기존의 것을 능가하고 있습니다. 게다가 환자의 컴플라이언스가 향상되었기 때문에 이러한 방법의 배합률이 상승하여 산업 확대에 박차를 가하고 있습니다. 또한, 주요 제약회사는 국제시장에서의 질병 치료 수요 증가에 대응하기 위해 제품 개발, 제조, 상업화를 위한 공동연구 및 제휴 등의 노력을 하고 있습니다.

예를 들어, 2021년 11월, STADA Arzneimittel과 Bioglan은 PD 환자의 치료에 사용되는 의약품 Lecigon(레보도파/카르비도파/엔타카폰)의 생산 능력을 확대하기 위해 파트너십을 체결했습니다. 따라서 PD 환자의 치료에 사용되는 의약품에 대한 수요 증가는 산업 성장을 가속할 것으로 예상됩니다. 그러나 신경내과 의사의 수가 제한되어 환자의 대기 시간이 길어지거나 병원에서 신경 외과 의사의 신규 채용이 어려워지는 등의 문제가 발생하고 있습니다. 또한, 현재 개업중인 신경과 의사 중 일부는 신규 메디케이드 환자의 수락을 피하는 의사도 있으므로 다른 의사로 변경하려는 환자에게는 어려움이 있습니다. 미국 신경학회(AAN)의 보고서에 따르면 2025년까지 신경내과의가 약 19% 부족할 것으로 예측됩니다.

파킨슨병 치료 시장 보고서 하이라이트

  • 칼비도파-레보도파 제제는 진전, 경직, 서맥 등의 증상에 대한 효능이 오랜 세월에 걸쳐 확립되어 왔기 때문에 파킨슨병 치료 시장을 독점해 2024년에는 25.12%의 최대 매출 점유율을 차지했습니다.
  • 소매 약국 부문은 2024년 41.59%의 수익 점유율로 파킨슨병 치료 시장을 독점하였고, 환자에게 널리 이용하기 쉽고 편리하기 때문에 예측 기간 동안 가장 빠른 성장이 예상됩니다.
  • 북미는 높은 유병률, 선진적 의료 인프라, 대규모 연구개발 투자 등의 요인이 겹쳐 2024년 매출 점유율 38.03%로 파킨슨병 치료 시장을 독점했습니다.
  • 아시아태평양의 파킨슨병 치료 산업은 의료지출 증가, 인구 고령화, 신경학적 건강에 대한 소비자의 의식 증가 등을 배경으로 급속한 성장을 이루고 있습니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 파킨슨병 치료 시장의 변수, 동향 및 범위

  • 시장 계통 전망
    • 모 시장 전망
    • 관련 및 부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 파킨슨병 치료 시장 분석 도구
    • 산업 분석-Porter's Five Forces 분석
    • PESTEL 분석

제4장 파킨슨병 치료 시장 : 약제 클래스별 추정 및 동향 분석

  • 부문 대시보드
  • 파킨슨병 치료 시장 : 약품 클래스별 변동 분석
  • 약제 클래스별 파킨슨병 치료 시장
  • 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 칼비도파-레보도파
  • 도파민 작용제
  • MAO-B 억제제
  • COMT 억제제
  • 항콜린제
  • 기타

제5장 파킨슨병 치료 시장 : 유통 채널별 추정 및 동향 분석

  • 부문 대시보드
  • 파킨슨병 치료 시장 : 유통 채널별 변동 분석
  • 유통 채널별 파킨슨병 치료 시장 전망
  • 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제6장 파킨슨병 치료 시장 : 지역별 추정 및 동향 분석

  • 지역 대시보드
  • 시장 규모 및 예측 동향 분석(2018-2030년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제7장 경쟁 구도

  • 시장 진출기업 분류
  • 주요 시장 진출기업에 의한 최근의 동향 및 영향 분석
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업 프로파일
    • Cerevel Therapeutics
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Merck &Co., Inc.
    • GlaxoSmithKline plc.(GSK)
    • AbbVie, Inc.
    • H. Lundbeck A/S
    • Amneal Pharmaceuticals LLC
    • Supernus Pharmaceuticals, Inc.
AJY 25.03.17

Parkinson's Disease Treatment Market Growth & Trends:

The global parkinson's disease treatment market size is expected to reach USD 7.58 billion by 2030, registering a CAGR of 5.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson's Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson's Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson's Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

Parkinson's Disease Treatment Market Report Highlights:

  • The carbidopa-levodopa segment dominated the Parkinson's disease treatment industry and accounted for the largest revenue share of 25.12% in 2024 due to its long-established efficacy in managing symptoms, particularly tremors, stiffness, and bradykinesia.
  • The retail pharmacy segment dominated the Parkinson's disease treatment market with the revenue share of 41.59% in 2024 and is anticipated to witness the fastest growth over the forecast period due to its widespread accessibility and convenience for patients.
  • North America dominated the Parkinson's disease treatment market with a revenue share of 38.03% in 2024 due to a combination of factors such as a high prevalence of the disease, advanced healthcare infrastructure, and significant research and development investments.
  • The Asia Pacific Parkinson's disease treatment industry is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of neurological health.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Parkinson's Disease Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advancements in treatment options
      • 3.2.1.2. Rising prevalence of Parkinson's disease
      • 3.2.1.3. Increased research and investment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Regulatory and Reimbursement Challenges
  • 3.3. Parkinson's Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Parkinson's Disease Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Parkinson's Disease Treatment Market: Drug Class Movement Analysis
  • 4.3. Parkinson's Disease Treatment Market by Drug Class (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Carbidopa-Levodopa
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dopamine Agonists
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. MAO-B Inhibitors
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. COMT Inhibitors
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Anticholinergics
    • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Parkinson's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Parkinson's Disease Treatment Market: Distribution Channel Movement Analysis
  • 5.3. Parkinson's Disease Treatment Market by Distribution Channel Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
  • 5.5. Hospital Pharmacy
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Retail Pharmacy
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Online Pharmacy
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Parkinson's Disease Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Cerevel Therapeutics
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Novartis AG
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Teva Pharmaceutical Industries Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Merck & Co., Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. GlaxoSmithKline plc. (GSK)
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. AbbVie, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. H. Lundbeck A/S
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amneal Pharmaceuticals LLC
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Supernus Pharmaceuticals, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제